Opinion

Video

Immunotherapy-Based Treatment Strategies in Advanced NSCLC

Eduardo Santos, MD, FACP, FCCP, provides an overview of immunotherapy-based treatment strategies for advanced NSCLC, outlining key factors influencing treatment selection.

Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.